{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,19]],"date-time":"2026-08-19T05:25:31Z","timestamp":1787117131656,"version":"build-2736575974"},"reference-count":41,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,8,19]],"date-time":"2026-08-19T00:00:00Z","timestamp":1787097600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100011727","name":"Stockholm l\u00e4ns landsting","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100011727","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004047","name":"Karolinska Institutet","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004047","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Endocrinol."],"abstract":"<jats:sec>\n                    <jats:title>Purpose<\/jats:title>\n                    <jats:p>The primary aim was to study the differences between pheochromocytomas (PCC) and sympathetic paragangliomas (PGL) in management and short- and long-term outcomes.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>This was a retrospective study of 220 patients that had undergone surgery for PCC or PGL and had been managed during the period 2005\u20132025 at the Department of Endocrinology, Karolinska University Hospital. Patient data were collected from electronic medical journals.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Patients with PCC compared to PGL had a longer duration of preoperative treatment with alpha-adrenergic receptor antagonist (50.0 vs. 34.0 days,\n                      <jats:italic>p<\/jats:italic>\n                      \u00a0=\u00a00.014) and shorter hospital stay (4.0 vs. 7.0 days,\n                      <jats:italic>p<\/jats:italic>\n                      \u00a0&amp;lt;\u00a00.001). Patients with PCC presented more often with dysglycemia (42.2% vs. 17.6%,\n                      <jats:italic>p<\/jats:italic>\n                      \u00a0=\u00a00.012), and glucose improved to a greater extent as well after surgery (84.2% vs. 33.3%,\n                      <jats:italic>p<\/jats:italic>\n                      \u00a0=\u00a00.033). Patients with PGL were more affected by new related tumors (recurrence, metastases, or metachronous tumor) during the follow-up time (27.8% vs. 11.0%;\n                      <jats:italic>p<\/jats:italic>\n                      \u00a0=\u00a00.019).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>There are many similarities between PCC and PGL; however, patients with PGL had a somewhat worse prognosis regarding short- and long-term outcomes, including longer length of stay at the hospital, risk for new associated tumors, and less positive effects on dysglycemia.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fendo.2026.1855363","type":"journal-article","created":{"date-parts":[[2026,8,19]],"date-time":"2026-08-19T04:41:40Z","timestamp":1787114500000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Differences in management and outcomes between pheochromocytomas and sympathetic paragangliomas"],"prefix":"10.3389","volume":"17","author":[{"given":"Mikaela","family":"Hermansson Salmi","sequence":"first","affiliation":[{"name":"Department of Molecular Medicine and Surgery, Karolinska Institute","place":["Stockholm, Sweden"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jan","family":"Calissendorff","sequence":"additional","affiliation":[{"name":"Department of Molecular Medicine and Surgery, Karolinska Institute","place":["Stockholm, Sweden"]},{"name":"Department of Endocrinology, Karolinska University Hospital","place":["Stockholm, Sweden"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Henrik","family":"Falhammar","sequence":"additional","affiliation":[{"name":"Department of Molecular Medicine and Surgery, Karolinska Institute","place":["Stockholm, Sweden"]},{"name":"Department of Endocrinology, Karolinska University Hospital","place":["Stockholm, Sweden"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,8,19]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1210\/jendso\/bvac105","article-title":"Systematic review: incidence of pheochromocytoma and paraganglioma over 70 years","volume":"6","author":"Al Subhi","year":"2022","journal-title":"J Endocr Soc"},{"key":"B2","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1007\/s12022-022-09704-6","article-title":"Overview of the 2022 WHO classification of paragangliomas and pheochromocytomas","volume":"33","author":"Mete","year":"2022","journal-title":"Endocr Pathol"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.3390\/cancers14040917","article-title":"Pheochromocytomas and abdominal paragangliomas: a practical guidance","volume":"14","author":"Calissendorff","year":"2022","journal-title":"Cancers"},{"key":"B4","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1210\/endrev\/bnab019","article-title":"Personalized management of pheochromocytoma and paraganglioma","volume":"43","author":"N\u00f6lting","year":"2021","journal-title":"Endocr Rev"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1210\/clinem\/dgaa982","article-title":"Metastatic pheochromocytomas and abdominal paragangliomas","volume":"106","author":"Granberg","year":"2021","journal-title":"J Clin Endocrinol Metab"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2014-1498","article-title":"Pheochromocytoma and paraganglioma: an endocrine society clinical practice guideline","volume":"99","author":"Lenders","year":"2014","journal-title":"J Clin Endocrinol Metab"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1530\/EC-17-0321","article-title":"Initial clinical presentation and spectrum of pheochromocytoma: a study of 94 cases from a single center","volume":"7","author":"Falhammar","year":"2018","journal-title":"Endocr Connect"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1530\/EJE-19-0159","article-title":"Pheochromocytoma and paraganglioma: clinical feature-based disease probability in relation to catecholamine biochemistry and reason for disease suspicion","volume":"181","author":"Geroula","year":"2019","journal-title":"Eur J Endocrinol"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1016\/j.beem.2024.101953","article-title":"Update on clinical characteristics in the evaluation of phaeochromocytoma and paraganglioma","volume":"38","author":"Berends","year":"2024","journal-title":"Best Pract Res Clin Endocrinol Metab"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra1806651","article-title":"Pheochromocytoma and paraganglioma","volume":"381","author":"Neumann","year":"2019","journal-title":"N Engl J Med"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.3390\/jcm9082435","article-title":"Cardiovascular manifestations and complications of pheochromocytomas and paragangliomas","volume":"9","author":"Y-Hassan","year":"2020","journal-title":"J Clin Med"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejso.2025.110144","article-title":"Progress in treatment and follow-up of pheochromocytoma","volume":"51","author":"Zhou","year":"2025","journal-title":"Eur J Surg Oncol"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.15386\/mpr-2741","article-title":"Evolution of metabolic disorders after resection of pheochromocytomas and paragangliomas: a single-center study","volume":"98","author":"Bentebbaa","year":"2025","journal-title":"Med Pharm Rep"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1530\/EC-25-0714","article-title":"Long-term persistent hypertension following surgical resection of pheochromocytoma and paraganglioma","volume":"15","author":"Jiang","year":"2026","journal-title":"Endocr Connect"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1016\/j.mce.2024.112344","article-title":"Metastatic pheochromocytoma and paraganglioma: integrating tumor biology in clinical practice","volume":"592","author":"Varghese","year":"2024","journal-title":"Mol Cell Endocrinol"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2023.1279828","article-title":"Local recurrence and metastatic disease in pheochromocytomas and sympathetic paragangliomas","volume":"14","author":"Araujo-Castro","year":"2023","journal-title":"Front Endocrinol"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2010-1946","article-title":"Clinical risk factors for Malignancy and overall survival in patients with pheochromocytomas and sympathetic paragangliomas: primary tumor size and primary tumor location as prognostic indicators","volume":"96","author":"Ayala-Ramirez","year":"2011","journal-title":"J Clin Endocrinol Metab"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1210\/jendso\/bvae093","article-title":"Identification of predictors of metastatic potential in paragangliomas to develop a prognostic score (PSPGL)","volume":"8","author":"Iguchi","year":"2024","journal-title":"J Endocr Soc"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2025.1597908","article-title":"Sex differences in management and outcomes in pheochromocytomas and paragangliomas","volume":"16","author":"Dahl","year":"2025","journal-title":"Front Endocrinol"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1007\/s12020-018-1734-x","article-title":"Treatment and outcomes in pheochromocytomas and paragangliomas: a study of 110 cases from a single center","volume":"62","author":"Falhammar","year":"2018","journal-title":"Endocrine"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1210\/js.2019-00200","article-title":"Presentation, treatment, histology, and outcomes in adrenal medullary hyperplasia compared with pheochromocytoma","volume":"3","author":"Falhammar","year":"2019","journal-title":"J Endocr Soc"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2025.1463945","article-title":"Sex differences in presentation of pheochromocytoma and paraganglioma","volume":"16","author":"Ali","year":"2025","journal-title":"Front Endocrinol"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1111\/cen.70002","article-title":"Differences in clinical presentation between pheochromocytomas and paragangliomas","volume":"103","author":"Pihlblad","year":"2025","journal-title":"Clin Endocrinol (Oxf)"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1093\/bjsopen\/zrad090","article-title":"Risk factors for postoperative complications after adrenalectomy for phaeochromocytoma: multicentre cohort study","volume":"7","author":"Parente","year":"2023","journal-title":"BJS Open"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2023.1174836","article-title":"Risk factors for postoperative complications after pheochromocytoma and\/or paraganglioma: a single-center retrospective study","volume":"13","author":"Ma","year":"2023","journal-title":"Front Oncol"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1016\/j.surg.2006.07.008","article-title":"Analysis of large versus small pheochromocytomas: operative approaches and patient outcomes","volume":"140","author":"Wilhelm","year":"2006","journal-title":"Surgery"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2023.1129622","article-title":"Surgical strategies of complicated pheochromocytomas\/paragangliomas and literature review","volume":"14","author":"Wang","year":"2023","journal-title":"Front Endocrinol"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1007\/s11701-020-01056-9","article-title":"Perioperative outcomes of laparoscopic, robotic, and open approaches to pheochromocytoma","volume":"14","author":"Fang","year":"2020","journal-title":"J Robot Surg"},{"key":"B29","doi-asserted-by":"publisher","first-page":"206","DOI":"10.1007\/s11701-025-02371-9","article-title":"Retrospective analysis of robotic versus laparoscopic surgery in the treatment of giant pheochromocytoma and paraganglioma","volume":"19","author":"He","year":"2025","journal-title":"J Robot Surg"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2025.1682912","article-title":"Prolonged alpha-blockade and doxazosin are associated with hypertensive crisis in pheochromocytoma surgery","volume":"16","author":"Zawadzka","year":"2026","journal-title":"Front Endocrinol"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2023.1139015","article-title":"Influence of duration of preoperative treatment with phenoxybenzamine and secretory phenotypes on perioperative hemodynamics and postoperative outcomes in pheochromocytoma and paraganglioma","volume":"14","author":"Yao","year":"2023","journal-title":"Front Endocrinol"},{"key":"B32","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1186\/s12872-024-03936-6","article-title":"Hypertension and cardiac damage in pheochromocytoma and paraganglioma patients: a large-scale single-center cohort study","volume":"24","author":"Yu","year":"2024","journal-title":"BMC Cardiovasc Disord"},{"key":"B33","doi-asserted-by":"publisher","first-page":"34","DOI":"10.4103\/iju.IJU_190_18","article-title":"Changes in blood pressure, blood sugar, and quality of life in patients undergoing pheochromocytoma surgery: a prospective cohort study","volume":"35","author":"Prakash","year":"2019","journal-title":"Indian J Urol IJU J Urol Soc India"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1002\/jso.27764","article-title":"Identification of risk factors for postoperative persistent hypertension in patients with pheochromocytoma","volume":"130","author":"Lu","year":"2024","journal-title":"J Surg Oncol"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1161\/01.hyp.29.5.1133","article-title":"Tumor recurrence and hypertension persistence after successful pheochromocytoma operation","volume":"29","author":"Plouin","year":"1997","journal-title":"Hypertens Dallas Tex 1979"},{"key":"B36","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1016\/j.ando.2020.01.001","article-title":"Prevalence and progression of carbohydrate disorders in patients with pheochromocytoma\/paraganglioma: retrospective single-center study","volume":"81","author":"Elenkova","year":"2020","journal-title":"Ann Endocrinol"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1530\/ERC-22-0218","article-title":"Glycemic disorders in patients with pheochromocytomas and sympathetic paragangliomas","volume":"29","author":"Araujo-Castro","year":"2022","journal-title":"Endocr Relat Cancer"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1016\/j.eprac.2024.11.004","article-title":"Glucose disorders in patients with pheochromocytoma\/paraganglioma: profile and influence effects in a large cohort with 705 patients","volume":"31","author":"Zhang","year":"2025","journal-title":"Endocr Pract Off J Am Coll Endocrinol Am Assoc Clin Endocrinol"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2020.593780","article-title":"Glucose intolerance on phaeochromocytoma and paraganglioma-the current understanding and clinical perspectives","volume":"11","author":"Abe","year":"2020","journal-title":"Front Endocrinol"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.3390\/jcm7090242","article-title":"Risk stratification on pheochromocytoma and paraganglioma from laboratory and clinical medicine","volume":"7","author":"Kimura","year":"2018","journal-title":"J Clin Med"},{"key":"B41","doi-asserted-by":"publisher","first-page":"862","DOI":"10.1210\/endrev\/bnad011","article-title":"Biochemical assessment of pheochromocytoma and paraganglioma","volume":"44","author":"Eisenhofer","year":"2023","journal-title":"Endocr Rev"}],"container-title":["Frontiers in Endocrinology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fendo.2026.1855363\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,19]],"date-time":"2026-08-19T04:41:46Z","timestamp":1787114506000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fendo.2026.1855363\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,19]]},"references-count":41,"alternative-id":["10.3389\/fendo.2026.1855363"],"URL":"https:\/\/doi.org\/10.3389\/fendo.2026.1855363","relation":{},"ISSN":["1664-2392"],"issn-type":[{"value":"1664-2392","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,19]]},"article-number":"1855363"}}